QuantRx/Jant Pharmacal
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics firm QuantRx Biomedical enters into a memorandum of understanding with rapid immuno-diagnostic test maker Jant Pharmacal to develop and market new diagnostics and monitoring technologies and products, the firms announce March 5. QuantRx and Jant are exploring point-of-care technologies in oncology, cardiovascular and other emerging markets. They expect to begin clinical trials soon and plan to launch several new products in 2008